Abstract |
Combination chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin ( M-VAC regimen) or with methotrexate, etoposide and cisplatin ( MEP regimen) was administered to 32 patients with advanced measurable uroepithelial cancers. Fifteen patients among them were adequately treated with M-VAC regimen, and 11 with MEP regimen. Complete remission was not achieved clinically in any patients. Partial remission occurred in 73.3% (11/15) of M-VAC patients and 72.7% (8/11) of MEP patients. Of eleven MEP patients, six were treated with MEP therapy as second line chemotherapy for the recurrence after other chemotherapy (5 cases after M-VAC, 1 case after intraarterial cisplatin). They showed a considerable response (4 patients, PR; 2 patients, MR) and an appreciable remission period, not inferior to those of first line chemotherapy with M-VAC regimen. The present study shows that MEP may be a promising regimen for advanced uroepithelial cancers, especially as a second line chemotherapy for relapsed cases after M-VAC therapy.
|
Authors | T Seguchi, E Nakano, T Miki, M Kondoh, K Nishimura, N Nakamura, A Okuyama |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 21
Issue 1
Pg. 59-65
(Jan 1994)
ISSN: 0385-0684 [Print] Japan |
PMID | 8291917
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
- Vinblastine
- Etoposide
- Doxorubicin
- Cisplatin
- Methotrexate
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cisplatin
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Drug Administration Schedule
- Etoposide
(administration & dosage)
- Female
- Humans
- Male
- Methotrexate
(administration & dosage)
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Remission Induction
- Ureteral Neoplasms
(drug therapy)
- Urinary Bladder Neoplasms
(drug therapy)
- Vinblastine
(administration & dosage)
|